0000950170-24-002598.txt : 20240105
0000950170-24-002598.hdr.sgml : 20240105
20240105190209
ACCESSION NUMBER: 0000950170-24-002598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240105
DATE AS OF CHANGE: 20240105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38360
FILM NUMBER: 24517923
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Solid Biosciences Inc.
CENTRAL INDEX KEY: 0001707502
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 900943402
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
BUSINESS PHONE: 617-337-4680
MAIL ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
FORMER COMPANY:
FORMER CONFORMED NAME: Solid Biosciences, LLC
DATE OF NAME CHANGE: 20170524
4
1
ownership.xml
4
X0508
4
2024-01-03
false
0001707502
Solid Biosciences Inc.
SLDB
0001197032
SMITH IAN F
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR
CHARLESTOWN
MA
02129
true
false
false
false
false
Common Stock
2024-01-03
4
M
false
15570
A
99948
D
Restricted Stock Units
2024-01-03
4
M
false
15570
0.00
D
Common Stock
15570
0
D
Stock Option (Right to Buy)
5.76
2024-01-03
4
A
false
15112
0.00
A
2034-01-03
Common Stock
15112
15112
D
Restricted Stock Units
2024-01-03
4
A
false
13021
0.00
A
Common Stock
13021
13021
D
Restricted stock units convert to common stock on a one-for-one basis.
The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.
The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").
/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith
2024-01-05